Could less be more? new study tests lower drug dose to keep AML in check

NCT ID NCT07163793

Recruiting now Disease control Sponsor: Northwell Health Source: ClinicalTrials.gov ↗

First seen Oct 31, 2025 · Last updated May 23, 2026 · Updated 30 times

Summary

This study looks at whether a lower dose of the drug venetoclax can be safely given to people whose acute myeloid leukemia (AML) is in remission. The goal is to reduce serious side effects like low white blood cell counts while still preventing the cancer from coming back. About 41 adults who have completed initial treatment will take part, and researchers will monitor their blood counts and overall health over several months.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA IN REMISSION are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Zuckerberg Cancer Center
RECRUITING

New Hyde Park, New York, 11042, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

ACUTE MYELOID LEUKEMIA IN REMISSION